Open an account

Innoviva

INVA · NASDAQ

$21.28+$0.20 (+0.95%)TodayMarket closed ·
Prev close $21.08

About INVA

Innoviva, Inc. engages in the development, commercialization, and financial management of biopharmaceuticals. The company is headquartered in Burlingame, California and currently employs 159 full-time employees. The company went IPO on 2004-10-05. The firm's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The firm's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.

Employees
159
Headquarters
Burlingame, California
Listed
Oct 5, 2004
Sector
Health Care
Industry
Pharmaceuticals
Website
inva.com

INVA key statistics

Market cap
1.52B
Price-earnings ratio
5.13
Dividend yield
—
Average volume
912.50K
Volume
507.58K
Open price
$21.31
High today
$21.49
Low today
$21.12
52 Week high
$25.15
52 Week low
$17.12

Innoviva (INVA) at a glance

As of Oct 20, 2026, Innoviva (INVA) shares are priced at $21.28, giving the company a market cap of 1.52B and a price-to-earnings ratio of 5.13.

Today the stock has traded between $21.12 and $21.49. The current price is 0.8% above the day's low and 1.0% below its high.

Volume so far is 507.58K shares, below the average of 912.50K shares a day.

Over the past year Innoviva has ranged from $17.12 to $25.15, and now sits 52% of the way up that range.

Innoviva met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$1.14 per share against an estimate of $0.4447.

The average analyst price target is $35.70, 67.8% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $35.70
Low
$18.18
Now
$21.28
High
$48.30

INVA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 138.7% on average.

  1. Q3 FY24: reported $0.02 per share against an estimate of $0.2703
  2. Q4 FY24: reported $0.26 per share against an estimate of $0.3774
  3. Q1 FY25: reported -$0.74 per share against an estimate of $0.2958
  4. Q2 FY25: reported $0.77 per share against an estimate of $0.51
  5. Q3 FY25: reported $1.08 per share against an estimate of $0.4922
  6. Q4 FY25: reported $1.94 per share against an estimate of $0.561
  7. Q1 FY26: reported -$0.05 per share against an estimate of $0.3978
  8. Q2 FY26: reported -$1.14 per share against an estimate of $0.4447

INVA news

  • Press releaseBusiness Wire

    Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026

  • Press releaseBusiness Wire

    Innoviva to Participate in Upcoming Investor Conferences

  • Press releaseBusiness Wire

    Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

  • Press releaseBusiness Wire

    Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

  • Press releaseBusiness Wire

    Nortiva Bio Launches to Develop Long-Acting Oral Medicines

  • Press releaseBusiness Wire

    Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy's for XACDURO® in Select International Markets

  • Press releaseBusiness Wire

    Innoviva to Participate in Upcoming Investor Conferences

  • Press releaseBusiness Wire

    Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

Similar companies

Companies in the same industry as Innoviva

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.